Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Decreases By 80.8%

Tharimmune, Inc. (NASDAQ:THAR) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 95,600 shares, a decline of 80.8% from the October 31st total of 496,900 shares. Currently, 6.6% of the company’s shares are sold short. Based on an average daily trading volume, of 1,180,000 shares, the days-to-cover ratio is currently 0.1 days.

Tharimmune Stock Up 3.5 %

THAR traded up $0.08 during midday trading on Wednesday, hitting $2.38. The company’s stock had a trading volume of 26,383 shares, compared to its average volume of 359,927. The firm has a 50-day moving average price of $2.37 and a two-hundred day moving average price of $3.16. Tharimmune has a 52-week low of $1.84 and a 52-week high of $16.20.

Institutional Trading of Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned 2.06% of Tharimmune as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.16% of the company’s stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).